



Universiteit
Leiden
The Netherlands

Clinical pharmacology studies investigating novel formulations of dopaminergic drugs

Thijssen, E.

Citation

Thijssen, E. (2024, June 12). *Clinical pharmacology studies investigating novel formulations of dopaminergic drugs*. Retrieved from <https://hdl.handle.net/1887/3763512>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3763512>

Note: To cite this publication please use the final published version (if applicable).

CURRICULUM VITAE

Eva Thijssen was born in Zevenaar, the Netherlands on November 23th, 1990. She graduated from secondary school (gymnasium) Liemers College in Zevenaar in 2009, after which she commenced her Bachelor study Biology at Wageningen University. She completed this cum laude in 2012 and continued her education at the Radboud University in Nijmegen, where she graduated cum laude in 2014 in Medical Biology. During her master's program, she performed an internship at the research group of Experimental Rheumatology at the Radboud Institute for Molecular Life Sciences. After her graduation, she started her first job here doing fundamental research in the field of osteoarthritis. In 2016, she changed jobs to work for a CRO where she was involved in monitoring phase 3 clinical trials. After these two jobs, it was clear that she was passionate about clinical research and she was therefore content to start as a Clinical Scientist at the Centre for Human Drug Research (CHDR) in 2018. Here she began her PhD trajectory as described in this thesis under supervision of prof. dr. G.J. Groeneveld, prof. dr. T. van Laar and dr. P.H.C. Kremer. Since 2023, Eva works as an Experienced Clinical Scientist at CHDR supervising Clinical Scientists. She has completed her training to become a board-certified Clinical Pharmacologist in 2024.

LIST OF PUBLICATIONS

- Thijssen E**, Tuk B, Cakici M, van Velze V, Klaassen E, Merkus F, van Laar T, Kremer PHC, Groeneveld GJ. Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients. *Clin Transl Sci.* (submitted Dec 2023).
- ZhuParris A, **Thijssen E**, Elzinga WO, Makai-Bölöni S, Kraaij W, Groeneveld GJ, Doll RJ. Treatment detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, part III estimation using finger tapping tasks. *Mov Disord.* 2023;38(10):1795-1805. doi:10.1002/mds.29520.
- Thijssen E**, Makai-Bölöni S, van Brummelen E, den Heijer J, Yavuz Y, Doll RJ, Groeneveld GJ. A placebo-controlled study to assess the sensitivity of finger tapping to medication effects in Parkinson's disease. *Mov Disord Clin Pract.* 2022 Sep 27;9(8):1074-1084. doi:10.1002/mdc3.13563.
- Thijssen E**, den Heijer JM, Puibert D, van Brummelen EMJ, Naranda T, Groeneveld GJ. Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson's disease patients. *Parkinsonism Relat Disord.* 2022;97:84-90. doi:10.1016/J.Parkreldis.2022.02.014.
- Thijssen E**, den Heijer JM, Puibert D, Moss L, Lei M, Hasegawa D, Keum K, Mochel K, Ezzeldin Sharaf M, Alfredson T, Zeng W, van Brummelen EMJ, Naranda T, Groeneveld GJ. A randomized trial assessing the safety, pharmacokinetics, and efficacy during morning OFF of AZ-009. *Mov Disord.* 2022;37(4):790-798. doi:10.1002/MDS.28926.
- Makai-Bölöni S, **Thijssen E**, van Brummelen EMJ, Groeneveld GJ, Doll RJ. Touchscreen-based finger tapping: Repeatability and configuration effects on tapping performance. *PLoS One.* 2021;16(12):e0260783. doi:10.1371/Journal.PONE.0260783.
- Vissers MFJM, Troyer MD, **Thijssen E**, Heuberger JAAC, Groeneveld GJ, Huntwork-Rodriguez S. A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls. *Clin Transl Sci.* 2023;00(1):1-13. doi:10.1111/CTS.13541.
- Yu HJ, **Thijssen E**, van Brummelen E, van der Plas JL, Radanovic I, Moerland M, Hsieh E, Groeneveld GJ, Dodart JC. A randomized first-in-human study with UB-312, a UB1Th® α -synuclein peptide vaccine. *Mov Disord.* 2022 Jul;37(7):1416-1424. doi:10.1002/mds.29016.
- den Heijer JM, Kruithof AC, van Amerongen G, de Kam ML, **Thijssen E**, Grievink HW, Moerland M, Walker M, Been K, Skerlj R, Justman C, Dudgeon L, Lansbury P, Cullen VC, Hilt DC, Groeneveld GJ. A randomized single and multiple ascending dose study in healthy volunteers of LT1-291, a centrally penetrant glucocerebrosidase activator. *Br J Clin Pharmacol.* 2021;87(9):3561-3573. doi:10.1111/bcp.14772.
- van Caam A, Madej W, **Thijssen E**, Garcia de Vinuesa A, van den Berg W, Goumans MJ, ten Dijke P, Blaney Davidson EN, van der Kraan PM. Expression of TGF β -family signalling components in ageing cartilage: age-related loss of TGF β and BMP receptors. *Osteoarthr Cartil.* 2016;24(7):1235-1245. doi:10.1016/J.Joca.2016.02.008.
- Thijssen E**, Van Caam A, Van Der Kraan PM. Obesity and osteoarthritis, more than just wear and tear: pivotal roles for inflamed adipose tissue and dyslipidaemia in obesity-induced osteoarthritis. *Rheumatology.* 2015;54(4):588-600. doi:10.1093/Rheumatology/Keu464.
- Blaney Davidson EN, van Caam APM, Vitters EL, Bennink MB, **Thijssen E**, van den Berg WB, Koenders MI, van Lent PLEM, van de Loo FAJ, van der Kraan PM. TGF- β is a potent inducer of Nerve Growth Factor in articular cartilage via the ALK5-Smad2/3 pathway. Potential role in OA related pain? *Osteoarthr Cartil.* 2015;23(3):478-486. doi:10.1016/J.Joca.2014.12.005.

